Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

rovisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, the timing and costs of these activities, the potential benefits of our product candidates, our key 2010 objectives, expectations regarding accrual of clinical trials and timing of release of results of studies, and our anticipated future expenses, revenues, reimbursements, capital and sufficiency of capital. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, uncertainties regarding our future operating results, the risk that our product candidates will not obtain the requisite regulatory approvals to commercialize or that the future sales of our product candidates may be less than expected, and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2009. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

               Condensed Consolidated Statements of Operations
                                 (unaudited)
                               (in thousands)

                                        Three months          Six months
                                       Ended June 30,        Ended June 30,

                                      2010       2009       2010       2009

    Collaboration revenue       
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Researchers often use microelectronic devices ... such devices can do much more – perhaps ... researchers have looked to patterned assemblies of proteins ... engineering to characterize – and potentially control – ... envisioned to recreate animal and human physiological functions ...
(Date:7/30/2014)... Calif. , July 30, 2014  AtheroNova ... the research and development of compounds to safely ... humans, today announces that its partner, CardioNova, has ... 1b clinical trial with AtheroNova,s lead compound, AHRO-001.  ... of the AHRO-001 Phase 1 safety trial completed ...
(Date:7/30/2014)... NCERC at Southern Illinois University ... findings on corn stover pretreatment methods at a ... Washington, D.C. , “Arun’s selection for presentation ... testament to the success of our postdoctoral fellowship ... the foresight and vision of SIUE and the ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
Breaking Biology Technology:UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... way of life at Meriter Hospital , a ... care to southern Wisconsin. Meriter includes a hospital, clinic, ... service. Formed from a merger of Madison General Hospital ... 430 active and associate physicians in over 30 medical ...
... from traditional paper phone bills to SBC eBill ... the "Save a StampHelp Save a Life" campaign, created in ... Inc. will contribute $1 dollar for every SBC customer that ... 15, 2004. , ,In 2004, an estimated 216,000 new cases ...
... Despite a two-year-plus economic recovery in the United States, ... which source you cite) have mysteriously failed to appear ... they not been created as expected? The list of ... recovery, uncertainty about the future, terrorism and the war ...
Cached Biology Technology:Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4Gone missing: Today jobs, tomorrow workers? 2Gone missing: Today jobs, tomorrow workers? 3
(Date:7/30/2014)... (125I) in cancer treatment has been shown to ... critical for neural transmission between the peripheral and ... from Institute of Radiation Medicine, Chinese Academy of ... implanted into rat dorsal root ganglia (DRG) to ... different radioactivity (0, 14.8, 29.6 MBq) were implanted ...
(Date:7/30/2014)... into a multitude of cells types. Researchers would like to ... of mature cells that make up the organs and other ... be long chains of sugars that dangle from proteins on ... of California, San Diego, has created synthetic molecules that can ... easily manipulated to direct the process, they report in the ...
(Date:7/30/2014)... SAN JOSE, Calif. , July 30, 2014 ... industry-academia partnership with the United States Air Force ... project proposed by Binghamton ... for human performance monitoring (HPM). The $425,000 project, ... and electronics packaging firm i3 Electronics, Inc. ( ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... life," but does today,s unprecedented level of dietary variety ... it might. According to ASN Spokesperson Shelley ... eating, itself- can trigger release of various brain chemicals, ... with drug addiction and withdrawal. And, as can happen ...
... Populations of spur-thighed tortoises ( Testudo graeca ), a species ... fires if outbreaks occur once every three decades or more. ... each fire. These are the results of a study by ... fire in the Sierra de la Carrasquilla mountains in Murcia ...
... is available in German . They live their lives ... upright position, sloths spend most of their lives hanging in trees ... slowly. Very slowly. But why are sloths so ,lazy,? And how ... lifestyle in the course of evolution? Zoologists of the Friedrich Schiller ...
Cached Biology News:Does food act physiologically like a 'drug of choice' for some? 2Tortoise populations can withstand fires every 30 years 2The decoding of slowness 2
...
... polyclonal to Endothelin B Receptor Like ... Receptor-Like Protein 2 (ETBR-LP-2) has been ... been isolated from human brain and ... Synthetic peptide (unfortunately, the amino acid ...
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
... 5 ml Dynabeads Epoxy (4.5 m). ... reactive groups. Ideal for coupling of antibodies ... on initial coupling with covalent binding of ... sulphydryll groups (SH)) occurring within 16-20 hours. ...
Biology Products: